Plasma Siglec-5 and CD163 as Novel Biomarkers for Fulminant Myocarditis
Fulminant myocarditis (FM) is the severest type of myocarditis and requires timely diagnosis and treatment. However, effective biomarkers for early diagnosis of FM are limited. First, 12 common inflammatory cytokines levels in the plasma of patients with FM were measured using human cytokine 12-Plex...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/11/2941 |
| _version_ | 1797465835357339648 |
|---|---|
| author | Yan Zhuang Jin Wang Huihui Li Yanghui Chen Chen Chen Dao Wen Wang |
| author_facet | Yan Zhuang Jin Wang Huihui Li Yanghui Chen Chen Chen Dao Wen Wang |
| author_sort | Yan Zhuang |
| collection | DOAJ |
| description | Fulminant myocarditis (FM) is the severest type of myocarditis and requires timely diagnosis and treatment. However, effective biomarkers for early diagnosis of FM are limited. First, 12 common inflammatory cytokines levels in the plasma of patients with FM were measured using human cytokine 12-Plex assay. Then, enzyme-linked immunosorbent assay (ELISA) was used to detect the plasma levels of another eight cytokines that we previously reported on. Moreover, a Spearman correlation test was employed to investigate the correlations between the plasma cytokine levels and the clinical parameters of patients with FM. Finally, receiver operating characteristic (ROC) curve analyses were performed to assess the diagnostic performance of plasma cytokine levels for the detection of FM. Five of the twelve common inflammation cytokines were significantly altered in patients with FM, but none of them was correlated with the severity of FM. Six of the eight significantly changed cytokines that we previously reported on were validated by ELISA. Among these, sST2, Siglec-5, and CD163 were negatively correlated with ejection fraction values. Furthermore, plasma Siglec-5 and CD163 levels were found to be associated with the severity of FM. Finally, both plasma Siglec-5 and CD163 showed outstanding diagnostic performance for FM. The current study identified plasma Siglec-5 and CD163 as valuable novel biomarkers for the early diagnosis of FM. |
| first_indexed | 2024-03-09T18:27:14Z |
| format | Article |
| id | doaj.art-484e613868e5495583ca05ee03c5a71f |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T18:27:14Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-484e613868e5495583ca05ee03c5a71f2023-11-24T07:46:32ZengMDPI AGBiomedicines2227-90592022-11-011011294110.3390/biomedicines10112941Plasma Siglec-5 and CD163 as Novel Biomarkers for Fulminant MyocarditisYan Zhuang0Jin Wang1Huihui Li2Yanghui Chen3Chen Chen4Dao Wen Wang5Division of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, ChinaDivision of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, ChinaDivision of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, ChinaDivision of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, ChinaDivision of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, ChinaDivision of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, ChinaFulminant myocarditis (FM) is the severest type of myocarditis and requires timely diagnosis and treatment. However, effective biomarkers for early diagnosis of FM are limited. First, 12 common inflammatory cytokines levels in the plasma of patients with FM were measured using human cytokine 12-Plex assay. Then, enzyme-linked immunosorbent assay (ELISA) was used to detect the plasma levels of another eight cytokines that we previously reported on. Moreover, a Spearman correlation test was employed to investigate the correlations between the plasma cytokine levels and the clinical parameters of patients with FM. Finally, receiver operating characteristic (ROC) curve analyses were performed to assess the diagnostic performance of plasma cytokine levels for the detection of FM. Five of the twelve common inflammation cytokines were significantly altered in patients with FM, but none of them was correlated with the severity of FM. Six of the eight significantly changed cytokines that we previously reported on were validated by ELISA. Among these, sST2, Siglec-5, and CD163 were negatively correlated with ejection fraction values. Furthermore, plasma Siglec-5 and CD163 levels were found to be associated with the severity of FM. Finally, both plasma Siglec-5 and CD163 showed outstanding diagnostic performance for FM. The current study identified plasma Siglec-5 and CD163 as valuable novel biomarkers for the early diagnosis of FM.https://www.mdpi.com/2227-9059/10/11/2941Siglec-5CD163biomarkerfulminant myocarditis |
| spellingShingle | Yan Zhuang Jin Wang Huihui Li Yanghui Chen Chen Chen Dao Wen Wang Plasma Siglec-5 and CD163 as Novel Biomarkers for Fulminant Myocarditis Biomedicines Siglec-5 CD163 biomarker fulminant myocarditis |
| title | Plasma Siglec-5 and CD163 as Novel Biomarkers for Fulminant Myocarditis |
| title_full | Plasma Siglec-5 and CD163 as Novel Biomarkers for Fulminant Myocarditis |
| title_fullStr | Plasma Siglec-5 and CD163 as Novel Biomarkers for Fulminant Myocarditis |
| title_full_unstemmed | Plasma Siglec-5 and CD163 as Novel Biomarkers for Fulminant Myocarditis |
| title_short | Plasma Siglec-5 and CD163 as Novel Biomarkers for Fulminant Myocarditis |
| title_sort | plasma siglec 5 and cd163 as novel biomarkers for fulminant myocarditis |
| topic | Siglec-5 CD163 biomarker fulminant myocarditis |
| url | https://www.mdpi.com/2227-9059/10/11/2941 |
| work_keys_str_mv | AT yanzhuang plasmasiglec5andcd163asnovelbiomarkersforfulminantmyocarditis AT jinwang plasmasiglec5andcd163asnovelbiomarkersforfulminantmyocarditis AT huihuili plasmasiglec5andcd163asnovelbiomarkersforfulminantmyocarditis AT yanghuichen plasmasiglec5andcd163asnovelbiomarkersforfulminantmyocarditis AT chenchen plasmasiglec5andcd163asnovelbiomarkersforfulminantmyocarditis AT daowenwang plasmasiglec5andcd163asnovelbiomarkersforfulminantmyocarditis |